Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Velban
(United States) [Available]Synonyms :
vinblastine
Class :
vinca alkaloid
Brand Name :
Velban
(United States) [Available]Synonyms :
vinblastine
Class :
vinca alkaloid
Dosage Forms & Strengths
Initial dose:
3.7
mg/m^2
Intravenous (IV)
usual dose: 5.5-7.4 mg per m2 IV once every 7 days <>br
Max: 18.5 mg per m2 once every seven days.
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3.
Initial dose:
3.7
mg/m^2
iv
usual dose: 5.5-7.4 mg per m2 IV once every 7 days
Max: 18.5 mg per m2 once every seven days
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3
initial dose:
3.7
mg/m^2
Intravenous (IV)
usual dose: 5.5-7.4 mg per m2 IV once every 7 days
Max: 18.5 mg per m2 once every seven days
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3
initial dose:
3.7
mg/m^2
iv
usual dose: 5.5-7.4 mg per m2 IV once every 7 days
Max: 18.5 mg per m2 once every seven days
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3
Chronic Lymphocytic Leukemia (Cll)
initial dose:
3.7
mg/m^2
Intravenous (IV)
usual dose: 5.5-7.4 mg per m2 IV once every 7 days
Max: 18.5 mg per m2 once every seven days
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3
6
mg/m^2
Intravenous (IV)
once a day
2
days
for every 3 to 4 weeks with apart of combination treatment
Dosage Forms & Strengths:
When vinblastine alone without combination with other drugs given, the initial dose :
6.5
mg/m^2
Intravenous (IV)
When used in combination with other drugs given, the initial dose of 6.5 mg per m2 IV
When vinblastine alone without combination with other drugs, the initial dose :
6.5
mg/m^2
Intravenous (IV)
When used with a combination of other drugs, the initial dose of 6.5 mg per m2 IV
when both drugs are combined, there may be an increased risk or severity of infection
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be an increased risk or severity of neutropenia
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased metabolism of vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be a decreased levels of serum concentration of vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be a decreased metabolism of atorvastatin
when both drugs are combined, there may be a decreased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased metabolism of dasatinib
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased excretion rate of fluvastatin
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be a decreased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased metabolism of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased metabolism of vinblastine
when both drugs are combined, there may be an increased metabolism of vinblastine
when both drugs are combined, there may be a decreased excretion rate of pitavastatin
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased metabolism of vinblastine
when both drugs are combined, there may be an increased metabolism of ruxolitinib
when both drugs are combined, there may be a decreased levels of serum concentration of selpercatinib
when both drugs are combined, there may be an increased metabolism of vinblastine
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may diminish the excretion rate when combined with vinca alkoloids, resulting in an enhanced serum level
when combined with vinblastine, the excretion of cholecystokinin may be decreased
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both the drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased risk or severity of adverse effects
may increase the risk or severity of toxic effects when combined
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the metabolism of each other when it is combined
when lenograstim is coupled with vinblastine, the risk or severity of peripheral neuropathy is enhanced
when both drugs are combined, there may be an increased metabolism of vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be an increased metabolism of etoposide
when both drugs are combined, there may be an increased metabolism of teniposide
Actions and Spectrum:
Actions:
Vinblastine combats cancer by stopping tumor cells from dividing. It targets a protein called tubulin, which helps form structures inside cells. By binding to tubulin, vinblastine causes microtubules to crystallize. This halts cell division or kills the cell. So vinblastine prevents cancer cells from growing and spreading.
Spectrum:
Vinblastine belongs to a group of medicines called vinca alkaloids. It’s combined with other chemo drugs to treat several cancers. These include non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, testicular cancer, Langerhans cell histiocytosis, resistant breast cancer, and gestational trophoblastic tumors. Vinblastine slows or stops cancer cells from growing in the body.
Adverse drug reactions:
Frequency defined
1-10%
Anemia
Alopecia
Leukopenia
Myelosuppression
Frequency Not Defined
Anorexia
Aspermia
Amenorrhea
Bronchospasm
Constipation
Diarrhea
Hypertension
Jaw pain
Nausea
Paralytic ileus
Peripheral neuropathy
Vomiting
Black Box Warning:
Follow these instructions closely under cancer doctors’ supervision. Inject the needle correctly into a vein before giving the medicine. If it leaks during IV, stop right away and use a different vein to avoid irritation. Use hyaluronidase and heat to disperse any leaked medicine and ease discomfort. Never inject this drug into the spinal cord, as it could be fatal.
Contraindication/Caution:
Contraindications
Cautions
Pregnancy Warnings:
Breastfeeding warnings:
Pregnancy Categories:
Pharmacology:
Vinblastine is a drug made from the periwinkle plant. It stops cells from dividing normally by attaching to proteins in the mitotic spindle, particularly during metaphase. Vinblastine impacts how cells use certain amino acids like glutamic acid. This disrupts processes like purine synthesis, the citric acid cycle, and urea formation. Most of vinblastine breaks down in the liver and gets eliminated through feces.
Pharmacodynamics:
Vinca alkaloids, like vinblastine, mainly act during the M (mitosis) and S (synthesis) phases of the cell cycle. They prevent microtubules from forming properly. Microtubules provide structural support for cells. Without them, the mitotic spindle can’t assemble correctly. This stops cell division. It also blocks DNA and RNA synthesis, keeping cells from replicating and moving through the cell cycle.
Pharmacokinetics:
Absorption
When taken, vinblastine reaches its peak concentration of 150 nanograms per milliliter in the blood.
Distribution
Vinblastine binds extensively to proteins in the body, accounting for 99% of how it’s distributed. It spreads widely, with a volume of 27.3 liters per kilogram.
Metabolism
The CYP3A4 enzyme metabolizes vinblastine, creating desacetylvinblastine.
Elimination and Excretion
Vinblastine has three half-lives: 4 minutes, 1.4 hours, and 24.8 hours. Most (99%) leaves the body through bile, while only 1% gets eliminated in urine.
Administration:
V Vinblastine gets administered via intravenous injection, usually once every 7 days by healthcare professionals. Any burning sensations, pain, or swelling around the IV site must be reported to caregivers. Regular medical tests track potential adverse effects which could influence cancer treatment timelines. Additionally, vinblastine may cause constipation, so consulting doctors for managing this side effect is advised.
Patient Information Leaflet:
Pronunciation: vin-blae-sti-n
Use: Vinblastine is an anti-cancer drug used for treating various cancers like Hodgkin’s disease, testicular cancer, bladder cancer, melanoma, non-small cell lung cancer, and ovarian cancer. Its mechanism disrupts cancer cell growth and spread throughout the body. Often combined with other chemotherapies, vinblastine enhances effectiveness against cancerous tumors.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
